Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Hope for kids with rare brain disease: new drug trial launches

NCT ID NCT07579910

First seen May 20, 2026 · Last updated May 22, 2026 · Updated 1 time

Summary

This study tests a new drug called tralesinidase alfa for children aged 1 to 5 with Sanfilippo syndrome type B, a rare genetic disease that damages the brain. The drug is given directly into the fluid around the brain and aims to slow down thinking and learning problems. About 14 children will take part, and the study will compare the drug to standard care over 5 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MPS IIIB are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

Explore the condition pages connected to this study.